March 23, 2009 - CircuLite Inc. said Daniel Burkhoff, M.D., Ph.D., CircuLite’s chief medical officer and adjunct associate professor of medicine at Columbia University Medical School, will present an abstract detailing long-term hemodynamic data on the Synergy Pocket Micro-Pump in a late-breaking session at the 58th Annual Scientific Session of the American College of Cardiology March 28-31 in Orlando, FL.
Synergy is a micro-blood pump, the size of a AA battery that can be implanted superficially in a “pacemaker-like” pocket. Synergy is the first and smallest device designed for partial circulatory support (up to 3L/min) and long-term use in patients with Class IIIb and early Class IV heart failure.
Abstract number 65205 is titled, “First Proof of Long-Term Hemodynamic Benefits of Partial Ventricular Support in Patients with Severe Heart Failure,” and will be presented , from 8:15-8:25 a.m. EDT Monday, March 30. The presentation will take place in Hall A2 of the Orange County Convention Center as part of session number 407, Late-Breaking Clinical Trials III – Emerging Technologies.
The company is also participating in a Texas Heart Institute satellite symposium focused on mechanical support. This symposium, titled, “Heart Failure: Surgical and Interventional Breakthroughs in Current Practice,” will take place from 8 a.m. to noon Saturday, March 28 at The Peabody Hotel in Orlando.
The company said the Synergy Pocket Micro-Pump represents a new approach to mechanical circulatory support that can transform chronic heart failure management by providing a less-invasive, elective treatment option for patients before their disease state becomes emergent. Synergy is the first implantable system designed to provide partial circulatory support (PCS) for long-term use in millions of unserved patients that have NYHA Class IIIb/early IV disease. The devices is currently only available for investigational use in the U.S.
CircuLite’s patented micro-pump provides up to 3L/min of flow, which increases total cardiac output, offloads the heart, allowing it to rest, and potentially enables beneficial recovery of heart function. The size of a AA battery, the device is small enough to be implanted subcutaneously in a “pacemaker-like” pocket through a minimally-invasive procedure.
For more information: www.CircuLite.net
November 18, 2024 
